Anti-vascular endothelial growth factor (VEGF) therapy has failed to improve survival in patients with breast cancer (BC). Potential mechanisms of resistance to anti-VEGF therapy include the up-regulation of alternative angiogenic and proinflammatory factors. Obesity is associated with hypoxic adipose tissues, including those in the breast, resulting in increased production of some of the aforementioned factors. Hence, we hypothesized that obesity could contribute to anti-VEGF therapy's lack of efficacy. We found that BC patients with obesity harbored increased systemic concentrations of interleukin-6 (IL-6) and/or fibroblast growth factor 2 (FGF-2), and their tumor vasculature was less sensitive to anti-VEGF treatment. Mouse models revealed that obesity impairs the effects of anti-VEGF on angiogenesis, tumor growth, and metastasis. In one murine BC model, obesity was associated with increased IL-6 production from adipocytes and myeloid cells within tumors. IL-6 blockade abrogated the obesity-induced resistance to anti-VEGF therapy in primary and metastatic sites by directly affecting tumor cell proliferation, normalizing tumor vasculature, alleviating hypoxia, and reducing immunosuppression. Similarly, in a second mouse model, where obesity was associated with increased FGF-2, normalization of FGF-2 expression by metformin or specific FGF receptor inhibition decreased vessel density and restored tumor sensitivity to anti-VEGF therapy in obese mice. Collectively, our data indicate that obesity fuels BC resistance to anti-VEGF therapy via the production of inflammatory and angiogenic factors.
INTRODUCTION
Antiangiogenic therapy in cancer patients has fallen short of expec tations (1, 2) . In metastatic breast cancer (BC) in particular, the U.S. Food and Drug Administration (FDA) revoked the approval of the vascular endothelial growth factor (VEGF) antibody bevacizumab because of a lack of overall survival benefit in phase 3 trials (3). There fore, understanding the mechanisms of resistance to antiVEGF treat ment and seeking potential biomarkers of response to antiVEGF are paramount. In metastatic colon cancer, obesity has been associated with reduced survival, specifically in patients receiving antiangiogenic therapies (4) . Reports for other cancers, such as metastatic kidney cancer, have been conflicting, whereas the effect of obesity on anti VEGF response in BC patients is unknown (5) (6) (7) .
Proinflammatory and alternative angiogenic factors can sustain angiogenesis and tumor progression despite VEGF blockade (1, (8) (9) (10) (11) . Many of these same factors are also increased in obesity, where the rate of adipose tissue expansion exceeds that of angiogenesis, result ing in inadequate tissue vascularization and hypoxia (12) (13) (14) (15) . In re sponse to hypoxia, cytokines and chemokines (adipokines) are released, causing inflammation and the recruitment of additional proinflam matory and proangiogenesis mediators (6, (16) (17) (18) (19) . Adipose tissue makes up a large proportion of BC, with cancerassociated adipo cytes (CAAs) being the predominant cell population in the stromal compartment of BCs (20) . Consistent with this, obesity can increase tumor inflammation (15, 21, 22) . Therefore, we hypothesized that obesity promotes resistance to antiVEGF therapy in BCs via systemic as well as local overproduction of inflammatory and alternative an giogenic factors.
Combining preclinical studies with a phase 2 clinical study of BC patients treated with antiVEGF, we found that multiple cell types contributed to the overproduction of interleukin6 (IL6) in tumors with obesity. Blockade of IL6 reverted obesityinduced resistance to antiVEGF therapy in primary and metastatic BC models. In addition, we found that fibroblast growth factor 2 (FGF2) was also associated with obesity and may contribute to resistance to antiVEGF. With 60 to 70% of BC patients presenting with excess weight at diagnosis (23) , this study is timely, provides relevant insight into the mechanisms underlying the poor efficacy of antiangiogenic therapy, and identifies potential strategies for overcoming these hurdles in BC patients.
RESULTS
In BC patients treated with anti-VEGF therapy, IL-6 correlates with worse outcome in patients with excess weight To evaluate the impact of obesity on response to antiVEGF in pa tients, we performed a subanalysis of a phase 2 clinical trial assess ing neoadjuvant bevacizumab therapy. Ninetynine patients with estrogen receptor-positive (ER + ) and triplenegative (TN) BC were treated with bevacizumab (monoclonal antibody against VEGF) alone for 2 weeks, followed by bevacizumab plus chemotherapy (Fig. 1A ) (24) . In the original study, only ~16% of patients presented with a pathologic complete response, confirming previous reports of the limited efficacy of antiVEGF therapy in BC (3) . We obtained body mass index (BMI) data (average BMI, 27.9) and measured the areas of visceral and subcutaneous adipose tissue (VAT and SAT, respec tively) by computerized tomography (CT) scan image analysis (Fig. 1B) . As expected, VAT and SAT strongly correlated with BMI ( fig. S1 ). We found that patients with a BMI ≥ 25 presented with 33% larger tumor size at baseline (4.1 versus 3.3 cm average size) compared to patients with a BMI < 25 (Fig. 1C ). In addition, we performed immunohis tochemical staining for tumor vessels in biopsy samples obtained be fore (day 0) and after (day 14) bevacizumab treatment ( Fig. 1D) . At day 0, tumor vessel density inversely correlated with adipose tissue area (Fig. 1E) . Consistent with this, expression of the hypoxia marker carbonic anhydrase IX (CAIX) positively correlated with VAT (Fig. 1F) . Both of these findings are reminiscent of the vascular impairment that characterizes adipose tissue in obesity (17, 25) . However, on day 14 of bevacizumab treatment, vessel densities and hypoxia became in dependent of patient VAT (Fig. 1, E and F). These data suggest that the differences in vessel density in patients with low and high adiposity were abrogated after bevacizumab treatment because of a greater sensitivity to this therapy in the low adiposity setting compared to the high adiposity setting. We then determined whether molecules associated with resistance to antiVEGF therapies (1, (8) (9) (10) (11) , such as IL6 and FGF2, were increased in the circulation of patients with obesity. We observed that plasma concentrations of IL6 (Fig. 1G , left) and FGF2 (Fig. 1H, top) positively correlated with the degree of adiposity (VAT). IL6, in particular, was increased at baseline and throughout the course of treatment in patients with elevated VAT, SAT ( Fig. 1G and fig. S2 ), and BMI measurements (Fig. 1G and fig. S3 ). Moreover, immunohistochemical observation of tumors in obesity revealed that IL6 and FGF2 expression in tumors was particularly abundant in adipocyterich regions (Fig. 1, G and H, images) . Collect ively, we found that patients with excess weight present with larger and more hypoxic tumors. These patients also had increased circulating concentrations of IL6 and FGF2, and expression of these factors in tumors was localized in close proximity to adipocyterich regions.
Diet-induced obesity attenuates the effect of anti-VEGF therapy on BC progression in mouse models
To dissect the role of obesity in BC response to antiVEGF therapy, high and lowfat diets were used to generate obese and lean mice [ Fig. 2, A and B ; individual body weight (BW) gain curves in fig. S4 ].
We used two syngeneic murine models reflecting ER + (E0771) and TN (MCaIV) BC subtypes (Fig. 2C) , similar to the patient populations studied. Obesity accelerated tumor growth in the early stages of tumor development, with tumors in obese mice becoming 50% larger in size compared to those in lean mice (~150 versus 100 mm 3 ) (figs. S5 and S6, A and B). However, once tumors reached this size range, the growth rate was identical between the lean and obese mice ( fig. S6A , from day 13 in obese mice and day 17 in lean mice onward, as also depicted in fig. S6C ). We assigned animals to control/treatment groups when tumors became established at a median volume of around 100 to 150 mm 3 (with minor variability between experiments), with tumor sizes being equally distributed in all control/treatment/diet groups in each experiment. After tumors were sizematched at around 125 mm 3 on day 0, tumor growth rates in lean versus obese control mice (no treatment) appeared indistinguishable, as depicted in Fig. 2D and  fig. S6C . Treatment with antimouse VEGF antibody (B204.1.1) was more effective at inhibiting tumor growth in lean compared to obese mice (Fig. 2 , D and E; individual curves in fig. S7 ). Nine days of B20 treatment reduced the E0771 and MCaIV tumor volumes in lean mice by 50 and 57%, respectively, but only by 12 and 28% in obese mice, respectively (Fig. 2, D and E). To determine whether the reduced sen sitivity of tumors in obesity to B20 treatment was due to diet or BW, a proportion of tumorbearing animals previously fed a lowfat diet were switched to a highfat diet. Tumor growth in animals that ex perienced a change in diet was similar to that observed in animals maintained on lowfat diet, indicating that BW, rather than diet, ac counted for the reduced sensitivity of tumors in obesity to B20 treat ment ( fig. S8 ). Together, these data indicate that antiVEGF therapy is less effective in inhibiting BC progression in obese mice.
The adipocyte-rich and hypoxic tumor microenvironment in obese mice is associated with reduced response to anti-VEGF therapy To determine why B20 failed to control tumors from obese animals to the same extent as in lean animals, we first assessed the effects of B20 on tumor vasculature. Similar to patients with obesity, E0771 tu mors from obese mice presented with lower vessel density (Fig. 3A ) and higher expression of hypoxia markers, namely, CAIX and glu cose transporter 1 (GLUT1), compared to tumors from lean mice ( Fig. 3B and fig. S9, A and B) . In addition, the phosphorylated forms of major regulators of cell proliferation and survival [extracellular signal-regulated kinase (ERK), AKT, and S6] were highly expressed in obese tumors and retained their expression even in the presence of antiVEGF therapy ( Fig. 3C; quantification in fig. S10 ). Conversely, in lean mice, the expression of the active forms of these mediators was relatively low and appeared to decrease after antiVEGF therapy ( Fig. 3C and fig. S10 ). These findings may account for the increased tumor burden in antiVEGF-treated obese mice compared to anti VEGF-treated lean mice (Fig. 2, D and E) . Furthermore, the hypo vascularity and hypoxia in tumors from obese animals were associated with increased presence of CAAs (Fig. 4A, left) . We further confirmed the presence of CAAs by detecting various adipocyte markers such as perilipin, Oil Red O staining, caveolin, and fatty acid synthase (FAS) (fig. S11, A to D) (26) . Not surprisingly, in obese tumors, we observed increases in both adipocyte size and number (Fig. 4, A and B) . More over, adipocyterich tumor areas had lower vessel density and were hypoxic (Fig. 4, C and D) . The expression of proliferative markers was particularly pronounced in tumor areas abundant in hypertrophic CAAs (Fig. 4, E and F) (27) . In addition, when tumorbearing animals were treated with B20, tumor tissue in adipocyterich regions re mained viable (nonnecrotic), whereas extensive necrosis was observed in adipocytepoor areas, suggesting a protective effect of adipose stroma in tumors (Fig. 4G and fig. S11E ).
Adipocytes and infiltrating myeloid cells in adipocyte-rich regions of mouse tumors overexpress IL-6
Similar to the enlarged adipocytes that form in adipose tissue during obesity, CAAs are associated with increased production of Bottom: Representative image of FGF-2 staining in a human breast tumor sample. Significant differences were assessed in (C) using t test and in (E) to (H) using Spearman's correlation test. *P < 0.05, **P < 0.01, ***P < 0.001. Data in (C) and (E) to (H) are shown as individual values, regression line, and box plots with minimum, maximum, and median values.
proangiogenic growth factors and pro inflammatory cytokines (15, 16, 21) . These growth factors and cytokines, when pres ent in the tumor microenvironment, can sustain angiogenesis and tumor progres sion despite blockade of VEGF signal ing (1, 9-11, 28, 29) . Consistent with the higher concentrations of IL6 observed in the plasma and adipocyterich tumor regions of BC patients with obesity, we found that E0771 tumors from obese mice presented with increased mRNA expres sion (more than fourfold) of Il6, Cxcl1, Cxcl3, Ifnß, and Lif (Fig. 5A) . A protein array for inflammatory cy tokines confirmed the robust increase in IL6, in addition to CXCL1, IL12, and TNF (tumor necrosis factor-) (Fig. 5B and fig. S12 ). IL6 concentrations in tumors from E0771 tumorbearing mice were increased at baseline in obese mice ( fig. S13 ), possibly reflecting the baseline increase in tumor hypoxia, because hypoxia can increase IL6 production (30, 31) . Similar to human tumor samples, IL6 ex pression was localized in adipocyterich regions of E0771 tumors and colocalized with the expression of hypoxia markers (Fig. 5, C and D). Double staining for cell surface markers and IL6 in tumor tissue revealed the cellular sources of IL6 to be adipocytes and in filtrating CD11b
+ myeloid cells, in particular F4/80 + macrophages (Fig. 5, E and F) . Consistent with the predominance of IL6 in hypoxic adipocyterich areas, macrophage infiltration was also more preva lent in these areas (Fig. 5G and fig. S14 ). We found that E0771 tumor cells express both the IL6 receptor (IL6R) and the IL6 signal transducing subunit gp130, indicating that IL6 can act directly on cancer cells to activate signaling pathways (Fig. 5H ). Consistent with (A) Schematic demonstrating the experimental design of preclinical studies. C57BL/6 and C3H mice were fed a high-fat diet (HFD; 60% fat) or a low-fat diet (LFD; 10% fat) from 6 weeks of age. Tumor cells/chunks were implanted 8 to 10 weeks after diet initiation, and treatments began when tumors reached ~100 to 150 mm 3 . (B) BW gain over time in C3H and C57BL/6 mice fed either an LFD or HFD (C57BL/6: LFD, n = 6; HFD, n = 7; C3H: LFD, n = 4; HFD, n = 4). Significant differences using two-way analysis of variance (ANOVA) with post hoc test for multiple comparisons are indicated. *P < 0.05, **P < 0.01, ****P < 0.0001. (C) Tumor/ cell protein extracts were used to access the expression of ER and epidermal growth factor receptor 2 (ERBB2) in tumors/cell lines. MCF7 and BT474 cell lines were used as positive controls for ER and (in the case of BT474) ERBB2 (antibody used detects both human and mouse HER2/ERBB2). Tubulin was used as loading control. (D and E) Tumor growth curves. E0771 (D) and MCaIV (E) tumors grown in obese versus lean mice were treated with anti-VEGF antibody (B20) or control immunoglobulin G (IgG) [E0771: n = 3 animals in obese control group and 6 animals for other groups; MCaIV: n = 8 animals in obese control group and 6 animals for other groups; two additional animals in the obese control group were removed after treatment (IgG) initiation because of failure of tumor growth]. Significant differences using two-way ANOVA with post hoc test for multiple comparisons are indicated. **P < 0.01, ****P < 0.0001 control versus B20 in lean or obese settings; # P < 0.05, ## P < 0.01, #### P < 0.0001, lean B20 versus obese B20. Data in (B), (D), and (E) are means ± SEM. a local release of IL6 by myeloid cells and adipocytes, we detected expression of phosphorylated signal transducer and activator of tran scription 3 (pSTAT3) particularly in cells localized adjacent to im mune cells and CAAs (Fig. 5I) . Overall, these results suggest that IL6 may be a rational target to overcome obesityinduced resistance to antiVEGF therapy.
IL-6 blockade overcomes resistance to anti-VEGF therapy in obese mice
Pharmacological inhibition of IL6 (~50% decreased concentration of IL6 in tumors; fig. S15) in combination with B20 treatment re duced tumor growth ( Fig. 6A ; individual curves in fig. S16 ) and me tastasis ( Fig. 6B and fig. S17 ) in obese mice to rates similar to lean mice receiving B20. IL6 blockade did not improve response to B20 in the lean setting, indicating that IL6 specifically mediates obesity induced resistance to antiangiogenic therapy. Deletion of hostderived IL6 using IL6 knockout (Il6 −/− ) mice reduced tumor IL6 by ~75%, suggesting that host stromal cells are the major source of IL6 pro duction in tumors ( fig. S15 ). The tumor growth curve for obese mice treated with anti-IL6 in combination with B20 did not vary much from that of obese Il6 −/− mice treated with B20 ( fig. S18 ). Conversely, IL6 inhibition alone did not alter tumor growth in the absence of VEGF inhibition even in the obese setting ( fig. S19 ). Together, these findings suggest that IL6 plays an important role in tumor progres sion but only in the context of obesity and VEGF blockade. In mice treated with B20, consistent with tumor growth data, IL6 inhibition decreased tumor cell proliferation ( Fig. 6C ) and number of mitoses in obese but not lean mice ( fig. S20 ), although attenuation of obesity induced signaling pathways like pSTAT3, pJNK (phosphorylated cJun Nterminal kinase), and pp38 was not observed in IL6-inhibited tumors ( Fig. 6D; quantification in fig. S21 ). B20 treatment increased necrosis, but addition of IL6 blockade to B20 did not fur ther increase the amount of necrosis ( fig. S22 ). In addition to its ef fects on tumor cells, anti-IL6 combined with antiVEGF therapy increased functional (perfused) vessel density (about sixfold; Fig. 6E , left) and decreased the expression of hypoxia marker CAIX by ~60% in obese animals (no effects were observed in lean mice) (Fig. 6E,  right) . Both hypoxia and IL6 can promote infiltration of immune cells, which may contribute to resistance to antiVEGF therapy by acting as additional sources of IL6 and other angiogenic and tumor promoting factors (29) . In obese mice, both genetic and pharmaco logical IL6 inhibition attenuated the B20induced infiltration of CD4 + CD25
+ regulatory T cells (Fig. 6F , left) and CD4 + T cells (Fig. 6F,  right) . Regulatory T cells, in particular, induce immunosuppression and tumor progression (32, 33) . Consistent with a decrease in im munosuppressive cell recruitment, IL6 inhibition reduced tumor concentrations of the prometastatic chemokine CXCL1 (34) in obese mice ( fig. S23 ). Together, these findings indicate that IL6 upregulation contributes to resistance to antiVEGF in obesity by sustaining tumor cell proliferation, reducing perfusion with associated aberrant hypoxic microenvironment, and promoting chemokine and immune cell re cruitment. Finally, we evaluated whether the addition of anti-IL6 could improve the efficacy of chemotherapy/antiVEGF combination treatment in BC. To this end, we used a suboptimal dose of doxorubicin (2 mg/kg) to mimic patient response in the clinical setting (35) . Con sistent with tumor growth data in Fig. 6A , the addition of IL6 inhi bition to B20 plus doxorubicin in obese animals prolonged the time to tumor progression to levels similar to those seen in lean mice that received B20/doxorubicin treatment, whereas in lean animals the triple combination therapy did not further enhance the efficacy of antiVEGF/doxorubicin (Fig. 6, G 
and H).
In the absence of obesity-promoted IL-6 up-regulation, FGF-2 may mediate resistance to anti-VEGF therapy in obesity In a second breast tumor model, we discovered that FGF2, but not IL6, was strongly associated with obesity. B20treated TN MCaIV tumors displayed higher gene expression of Fgf2, Il6, Tnf, Vegfa, and angiogenin (12, 3, 5, 2, and 4fold increases, respectively) in obese compared to lean animals (Fig. 7A) . Protein expression analysis confirmed increased FGF2, but not IL6, TNF, or VEGFA (Fig. 7B  and fig. S24 ). Akin to the increased IL6 expression in the E0771 model, baseline tumor FGF2 expression (both mRNA and protein) was increased in untreated obese mice compared to untreated lean mice ( fig. S25, A and B) . Similarly, FGF2 was expressed abundantly in adipocyterich areas toward the tumor periphery (Fig. 7C, top,  and fig. S25C ), as well as in activated cancerassociated fibroblasts (Fig. 7C, bottom, and fig. S25D ). These findings are consistent with the localization of FGF2 to adipocyterich regions in human BCs (Fig. 1H, bottom) and the association of obesity with circulating FGF2 in patients (Fig. 1H, top) . Considering that FGF2 has previ ously been implicated in resistance to antiangiogenic therapy (36) (37) (38) , this poses yet another potential mechanism of resistance to anti VEGF therapy induced by obesity. As seen in E0771 tumors, MCaIV tumors were less vascularized and more hypoxic when grown in obese L e a n L e a n mice ( Fig. 7D and figs. S26 and S27). Obesity also rendered B20 ineffective in reducing vessel density compared to lean mice (53% reduction) (Fig. 7D) . We next investigated the role of FGF2 in anti VEGF therapy resistance. Specific inhibition of the FGF receptor (FGFR) using antiFGFR (AZD4547, 12.5 mg/kg orally, once daily) improved tumor responsiveness to B20 in obese mice (Fig. 7E , green versus blue curves in the graph; individual curves in fig. S28 ), whereas in lean mice the improvement was not significant (Fig. 7E , brown versus orange curves). However, this treatment was associated with substantial BW loss in mice from all treated groups, suggesting sys temic toxicity ( fig. S29 ). Therefore, we sought nontoxic alternatives to reduce FGF2 in our model. The biguanide metformin-a clini cally used antidiabetes drug with a good safety profile-can reduce the cellular expression of FGF2 (39) and has promising anticancer effects in the obese setting (22, 40, 41) . We found that metformin reduced gene and protein expression of FGF2 in B20treated MCaIV tumors in obesity (Fig. 7, A and B) . We also observed that metformin treatment induced robust deactivation of FGF2 downstream signaling pathways such as AKT, S6, ERK, and STAT3 ( Fig. 7F ; quantification in fig. S30 ), reduced vessel density (Fig. 7 , G and H), and ultimately resensitized tumors to antiVEGF treatment in obese mice (Fig. 7I) . Although FGFR phosphorylation in metformintreated tumors was approximately half, the difference was not statistically significant ( fig. S30) . Notably, metformin also caused activation of adenosine 5′monophosphate-activated protein kinase/acetylCoA carboxylase (AMPK/ACC) in tumors ( Fig. 7F and fig. S30 ), suggesting that it may have direct effects on tumor cell signaling. Together, these data indicate that, in the absence of obesitypromoted IL6 upregulation as seen in the MCaIV/C3H model, FGF2 may mediate resistance to antiVEGF therapy in the obese setting by sustaining angiogenesis. Overall, we identified two complementary strategies to overcome BC resistance to antiVEGF therapy in obesity by targeting IL6 and/or FGF2 (Fig. 7J ).
DISCUSSION
The results from our clinical study and clinically relevant orthotopic tumor models reveal that obesity associates with hypovascularized and hypoxic tumors at diagnosis, accelerated tumor growth, and resistance to antiVEGF therapy in BC via increased secretion of IL6 and/or FGF2 from hypoxic adipocyterich regions in tumors. Pre vious studies have reported the role of IL6 or FGF2 in the context of resistance to antiangiogenic therapies (1, (8) (9) (10) (11) . This study, however, suggests that these molecules mediate obesityinduced resistance to antiVEGF therapy. In addition, given that conflicting findings have been reported for the same tumor type, such as when obesity was re ported to associate with both better and worse clinical outcomes in kidney cancer patients taking antiangiogenic therapies (5, 7), the ef fect of obesity in BC on antiVEGF therapy was unknown. (A) Tumor growth curves. E0771 tumors grown in lean versus obese C57BL/6 mice were treated with control IgG (lean, n = 9; obese, n = 6), B20 (lean, n = 6; obese, n = 7), or a combination of B20 and IL-6 inhibitor (lean, n = 8; obese, n = 7). ***P < 0.001, ****P < 0.0001 lean B20 versus obese B20; ) is depicted in the right. Significant differences using one-way ANOVA for (E) and (F) and two-way ANOVA for (A) to (C), (E), and (H) with post hoc multiple comparisons tests are indicated. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data in (A) are shown as means ± SEM and in (B), (C), (E), (F), and (H) are shown as individual values plus box plots with minimum, maximum, and median values. ; lean animals: control, n = 5; anti-FGFR, n = 4; B20, n = 5; B20 + anti-FGFR, n = 5; obese animals: control, n = 4; anti-FGFR, n = 4; B20, n = 8; B20 + anti-FGFR, n = 9). Significant differences using two-way ANOVA with post hoc multiple comparisons tests between B20 and B20 + anti-FGFR groups in both lean and obese conditions are indicated in the graph, ****P < 0.0001 in obese and NS (not significant) in lean (day 6). At day 9, a direct comparison between anti-FGFR and B20 + anti-FGFR groups was made for both lean and obese mice. Significant differences using t test, ## P < 0.01 in obese and NS in lean. The obese microenvironment promotes tumor resistance to antiangiogenic therapy. In breast tumors treated with anti-VEGF, obesity-induced IL-6 and FGF-2 production may mediate resistance to anti-VEGF via potentially distinct mechanisms. IL-6 sustains tumor cell proliferation, promotes immune cell recruitment, and drives dysfunctional angiogenesis that further aggravates hypoxia and promotes tumor progression despite anti-VEGF therapy. The proangiogenic factor FGF-2 sustains angiogenesis despite VEGF blockade. Significant differences using t test in (F); one-way ANOVA in (B) and (H) and two-way ANOVA in (D), (E), and (I) with post hoc multiple comparisons tests are indicated. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0. Here, we confirmed that breast adipose tissue tends to be invaded by the advancing BC (20, 42) . Furthermore, the increase in intratu moral adipocyte size and density that we observed in obese mice is also consistent with previous reports (17, 43, 44) , and adipocytes prox imal to tumors are hypoxic in BC patients (17, 43, 44) . These charac teristic findings may be due to the invasion of BC into the local breast adipose tissues, which are already hypoxic and hypovascular in the obese setting (13) . Notably, we observed increased tumor cell prolif eration in these adipocyterich regions, which remained viable despite antiVEGF therapy, whereas adipocytepoor areas tended to be necrotic. The abundance of these protumor adipocytes that arise in obese mouse tumors allowed for continuous tumor progression during antiVEGF treatment. Such protumor functions in the vicinity of intratumoral adipocytes have also been reported in nonobese mice (27, 42, (45) (46) (47) . In addition, E0771 BC cells proliferate faster when cocultured with adipocytes, and when coimplanted with these cells in mice, breast tumors grow faster and are more metastatic (27, 42, (46) (47) (48) . Here, we show that adipocyterich areas in tumors are associated with re sistance to antiVEGF therapy in obesity. Together, our findings indi cate that, under obese conditions, tumors grow in and adapt to (with upregulation of hypoxia adaptation factors, such as CAIX and GLUT1) the hypoxic microenvironment of obese adipose tissue. Thus, obese microenvironment-adapted BC cells are able to survive during antiVEGF therapy, whereas lean BC cells do not. These results corroborate previous reports showing that hypovascularization, hy poxia, or hypoxiarelated markers are associated with resistance to antiVEGF therapy (36, (49) (50) (51) (52) .
One of the mechanisms by which hypoxia may contribute to the resistance to antiangiogenic therapy is production of inflammatory cytokines and angiogenic factors by adipocytes and infiltrating my eloid cells (25, 36, (53) (54) (55) (56) (57) (58) (59) . We found the expression of IL6 and/or FGF2 in adipocytes, myeloid cells including macrophages (IL6), and fibroblasts (FGF2) preferentially in adipocyterich hypoxic re gions. These adiposerich regions were more prevalent in tumors from obese mice. Hence, IL6 and FGF2 were also higher as well. These findings further support the hypothesis that an intrinsic re sistance mechanism is already in place in BCs in obesity before anti VEGF therapy is initiated. Consistent with that, macrophages and IL6 expression are typically found in close proximity to dead adi pocytes in breast adipose tissue (56) . In addition, our results align with the finding in patients that adipocytes located near tumor cells upregulate IL6 production (27, 42, 55) . The link between IL6 and obesity is wellestablished (60) (61) (62) . In addition, transcriptomic anal ysis revealed marked upregulation of IL6 inflammatory pathway in the tumors of BC patients with obesity in comparison to those without obesity (63) . In our study, we found that IL6 increased with BW in BC patients and mice, was particularly expressed in adipose rich regions of tumors, and was associated with worse response to antiVEGF therapy. Although IL6 appeared to originate from adi pocytes and myeloid cells, CAAs seem to be the major contributor for the increased IL6 in tumors from obese mice. We have recently found that obesity did not promote infiltration of myeloid cells, monocytes, or macrophages in E0771 tumors (22) . Another study also found no difference in the expression of myeloid (CD11b + )-specific IL6 originating from E0771 tumors implanted in lean and obese mice (63) .
IL6 can influence all stages of tumor development and metasta sis (64, 65) , induce upregulation of CAIX, and promote a hypoxia resistant invasive phenotype in BC cells (66) . In addition, high plasma concentrations of IL6 have been associated with poor outcomes in cancer patients (kidney and liver cancer) treated with antiangiogenic agents, and IL6 inhibition improved response to antiVEGF in a mouse glioma model (10, 29, 65, 67) . Here, targeting IL6 in B20 treated E0771 breast tumors in obese mice decreased STAT3 signaling, tumor cell proliferation, tumor growth, and metastasis and increased survival. IL6R expression and the downstream mediator gp130 in E0771 cells are consistent with the effect on tumor cell proliferation. However, IL6 blockade was ineffective without obesity or antiVEGF therapy. It is possible that the abundance of IL6 in the obese setting predisposes obese tumors to respond to IL6 inhibition. In addition, IL6 may be a critical protumorigenic molecule only in the context of VEGF signaling blockade. IL6 can also regulate trafficking and recruitment of immune cells such as myeloid cells, which are a fur ther source of proinflammatory and protumorigenic cytokines and can induce tumor immunosuppression by induction of regulatory T cells (68) (69) (70) . In our study, IL6 inhibition reversed the B20induced re cruitment of immunosuppressive regulatory T cells in obese mice, suggesting that IL6 inhibition may potentiate immunotherapy espe cially in the obese setting. Furthermore, the addition of IL6 blockade to antiVEGF therapy improved blood vessel perfusion and tissue oxygenation, hallmarks of vascular normalization (2), in obese mice. This is consistent with findings in an asthma model, in which lung vascular permeability was decreased by IL6 inhibition (71) . As shown elsewhere (2), vascular normalization can improve concomitantly administered cytotoxic therapies, demonstrating additional benefit of the combination of antiVEGF with IL6 inhibition. In conclusion, IL6 blockade may prevent the effects of obesity on cell proliferation, vascular dysfunction, immune cell recruitment, and immunosuppression.
In addition to IL6, FGF2 was also increased in patients and mice with obesity. Adipocytes produce FGF2, and plasma FGF2 cor related with BMI (37, 72) . In addition, FGF pathway activation has been proposed as a mechanism of escape from VEGFtargeted ther apies (36) (37) (38) . Here, FGF inhibition using an FGFR inhibitor tested in clinical trials (73) or metformin sensitized tumors to antiVEGF treatment in obese but not in lean mice. In B20treated obese mice, metformin decreased tumor FGF2 at the gene and protein levels, as well as its downstream signaling and vessel density without any signs of toxicity. This is consistent with previous studies showing that metformin may be more effective in a hypoxic setting (74) and that it can decrease tumor vessel density induced by obesity to levels observed in lean mice (63) . These studies may explain the benefits recently re ported in a cancer patient when metformin was added to bevacizumab treatment (75) . In addition, metformin is particularly effective in the obese setting and likely acts via multiple mechanisms (22, 41) .
Epidemiological evidence suggests that BC patients who have obesity at diagnosis have a worse prognosis compared to patients without obesity (76) (77) (78) (79) . In particular, a metaanalysis of 43 studies that examined the association between obesity at diagnosis and BC outcome revealed that patients with obesity were 33% more likely to die of BC compared to patients without it (79) . Moreover, in a recent study with 137 ER + BC patients, those with obesity had lower overall and progressionfree survival (48) . For our clinical study, no data for recurrence, overall survival, or progressionfree survival are avail able yet, given the neoadjuvant setting and the recent completion of the study, which poses a limitation to our study. However, we observed 33% larger tumor size at diagnosis in patients with excess weight com pared to lean subjects, which was corroborated by our animal models. In addition, E0771 tumor cell growth was only modestly accelerated in obese compared to lean mice, particularly in the early stages of tumor growth. Although studies using the same tumor model have shown a similar growth pattern (80) Kolb et al. (63) versus purified nutrientmatched lowfat diet in our study], and environ ment where animals are located, which may affect the microbiota (animals in the Steele Laboratories are located in a gnotobiotic facility, which may differ from other groups). This point has also been raised recently by Scully et al. (80) , who, similar to our study, observed only a mild increase in E0771 tumor growth in obese mice (and similar vascular phenotypes, as discussed below). They stated that differences in the duration of feeding, the type of diet, age, or menopausal status of the mice may explain the different observations in the literature. Similarly, there have been inconsistent reports of the effect of obesity on tumor vessel density, which can also be explained by the factors discussed above. In particular, in the study by Kolb et al. (63) , the authors observed increased IL1, VEGFA, and vessel density in tu mors of obese mice, with the latter two returning to the concentra tions observed in lean mice after treatment with anti-IL1. In our study, neither IL1 nor VEGFA expression was affected by obesity in patients or mouse models, which may explain the differences in vessel density in these studies. On the other hand, Scully et al. (80) , using a similar E0771 model in lean and obese female C57BL/6, showed not only similar tumor growth behavior to our studies but also a sim ilar vessel density decrease in tumors from obese mice. They went on to conclude that the association between tumor vessel density and obesity not only is influenced by menopausal status but also is age and modeldependent.
These findings indicate that adipocytedense hypoxic areas in tu mors from individuals with obesity induce resistance to antiVEGF therapy by producing inflammatory cytokines and angiogenic factors such as IL6 or FGF2, which sustain vasculature and promote an immunosuppressive environment and tumor cell survival. Targeting these pathways with specific drugs, such as tocilizumab, an anti-IL6R antibody that has already been approved by FDA for other indications (82) , or other agents that affect these pathways, such as metformin, ultimately sensitizes primary and metastatic tumors to antiVEGF therapy in obesity. On the other hand, this study is consistent with recent evidence that weight management in BC patients may be an effective tool to improve prognosis (83) . Given the prevalence of obesity among BC patients, the lack of stratification by obesity status using BMI or VAT may explain the lack of overall survival benefit with antiVEGF therapy in BCs. Our work reveals strategies to improve the clinical outcome of BC. Whether stratifying patients based on obe sity or obesityrelated markers as well as inflammatory or angiogenic factors will allow a more personalized approach to BC treatment, and in particular whether targeting specific inflammatory or angiogenic pathways will overcome obesityinduced resistance to antiVEGF treatment, warrants prospective evaluation. Finally, because inflam mation and angiogenesis can affect response to conventional and other molecularly targeted therapies, the findings of this work may extend beyond antiVEGF treatment in BC.
MATERIALS AND METHODS

Study design
The objective of the present study was to evaluate the impact of obe sity on response to antiVEGF-targeted therapy. The sample sizes of the experiments were selected on the basis of previous experience. Data collection was stopped at a priori defined time points. Animal experiments were performed with an a priori hypothesis without rep etition. Experiments were carried out in an unblinded fashion except for analyses of immunohistochemistry images.
Statistical analysis
Statistical differences were assessed by twotailed Student's t test for comparisons between two groups, oneway ANOVA followed by post hoc multiple comparisons test when analyzing multiple pairs of in terest without a priori selection within the obese mouse population, twoway ANOVA with post hoc multiple comparisons test when comparing tumor growth and multiple treatment/genetic groups in lean and obese mice, and Spearman test for correlation between con tinuous variables. Density of adipocyterich or adipocytepoor regions in tumors from lean and obese mice was assessed using  2 test. Time to progression (survival curves) was estimated by KaplanMeier curves and compared using the logrank test. All statistical analyses were performed using GraphPad Prism software. A P value of less than 0.05 was considered to denote statistical significance as calculated by the appropriate statistical test. For more details on experimental procedures, please see the Supplementary Materials.
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